Several studies conducted in children and adults have demonstrated the good tolerability of Bricanyl in all its formulations. Adverse events are typical of beta2-agonists and are generally mild and infrequent, with incidence similar to that of other inhaled beta2-agonists. Problems are rarely reported, particularly after inhaled therapy used on an as-required basis.
Moreover, Bricanyl Turbuhaler has been shown to reduce adverse events further by eliminating those associated with the CFCs and lubricants used in pMDIs.
| 1. Pauwels RA, et al. Chest 1996; 110: 53–7 |
| |
In this 1-year study, patients receiving Bricanyl or Pulmicort via pMDI were randomized to continue receiving treatment via pMDI or switch to Turbuhaler. There was a significantly lower incidence of inhaler-induced symptoms with Turbuhaler than with pMDI
Inhaler-Induced Symptoms
Sum of cough, hoarseness, sore throat, sneeze and bad taste
An open, randomized, parallel-group study was conducted to investigate whether asthmatic patients (n = 1004) considered adequately treated with a glucocorticosteroid and/or short-acting beta2-agonist via pressurized metered-dose inhaler could be transferred to a corresponding nominal dose of budesonide and/or terbutaline via Turbuhaler.
Adapted from Pauwels et al., 1996.
Note: Bricanyl pMDI is no longer available. |
| |
| 2. Selroos O, et al. Thorax 1994; 49: 1228–30 |
| |
In hyperreactive asthmatic patients, inhalation from Turbuhaler avoided the possibility of acute bronchoconstriction that might occur following inhalation from pMDIs.
Avoidance of acute bronchoconstriction with Bricanyl Turbuhaler
Two double-blind, randomized, crossover studies were performed in 15 selected patients to investigate the true response to inhaled terbutaline; either 2.0 mg via pressurized metered-dose inhaler with Nebuhaler, or 1.0 mg via Turbuhaler.
Adapted from Selroos et al., 1994. |
| |
| 3. Blackhall MI and O'Donnell SR. Eur Respir J 1987; 71: 96–101 |
| |
This study showed that a cumulative dose of 4 mg terbutaline via pMDI* plus spacer could be given over a 1-hour period to asthmatic children without affecting pulse rate but with dose-related increases in lung function.
Increase in FEV1 versus pulse rate
Mean values for increase in FEV1and pulse rate after cumulative doses of either nebulized terbutaline or terbutaline from a metered-dose aerosol via Nebuhaler. This was carried out in a group of 12 children given each treatment randomly, but on different days.
Adapted from Blackhall et al., 1987.
*No longer available |
| |
back to top 
|
|
